ICER will assess the comparative clinical effectiveness and value of treatments for acute migraine, including: two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan); and a 5-HT1f agonist lasmiditan (Eli Lilly). All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019. The report will be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in January 2020.
For questions, please contact Ellie Adair, Program Manager, at email@example.com.
TBD – Chicago, IL
The Midwest CEPAC will convene to review ICER's assessment of acute migraine treatments.